A CASE OF CANDIDA ALBICANS SEPTICEMIA WITH GOOD PROCESS TREATED WITH A NEW ANTIFUNGAL AGENT, MICONAZOLE

NASU MASARU, GOTO YOICHIRO, GOTO JUN, SABURI YOSHIO, TASHIRO TAKAYOSHI, AKASHI MITSUNOBU, ITOGA TAKASHI, FUJISHIMA NOBUHIKO, SHIBATA OKIHIKO, UCHIDA YUZO, SHIRABE JOJI

doi:10.11250/chemotherapy1953.32.365

We have presented a case of Candida albicans septicemia which was cured with an antifungal imidazole derivative, miconazole, together with a few discussions. In this case, a 32-year-old man was operated on by rectectomy for colonic polyp. While he was under management by IVH, a high fever appeared, with C. albicans isolated from the venous blood, arterial blood and myelic blood. He was then treated with 800 to 1, 200mg daily of miconazole, every day, for 33 days (to a total dose of 30.2g), ran a favorable course, and was eventually' discharged. The treatment was associated with no side effects of the drug. The MICs of miconazole for the isolates were in the range from 0.39 to 0.78 μg/ml, and the blood level of the drug reached a peak of 0.90 μ g/ml following the administration of 400mg of the drug. We also compared the antibacterial activities of amphotericin B (AMPH), miconazole and 5-fluorocytosine (5-FC) against the 29 recent isolates of C. albicans from clinical materials. The antibacterial activity of AMPH was comparable to that of miconazole, with their MICs for the isolates distributed in the range of not more than 1.56 μ g/ml. The antibacterial activity of 5-FC was not as potent as those of the former. Because miconazole has proved to have a potent antibacterial activity, accompanied by a low incidence of side effects, we think that this drug will be a useful therapeutic agent for deep candidiasis.

A CASE OF <I>CANDIDA ALBICANS</I> SEPTICEMIA WITH GOOD PROCESS TREATED WITH A NEW ANTIFUNGAL AGENT, MICONAZOLE

Bibliographic Information

Description

Journal

Details 詳細情報について

Export

Report a problem